This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Lead SAH-FOXP3 peptides impeded Treg cell function and altered gene expression in vivo.
Why it matters
This research could pave the way for new therapies that enhance immune responses in conditions like cancer, where Treg cells inhibit effective treatment.
How the study worked
The study involved designing and synthesizing stapled peptides to block FOXP3 interactions, followed by biochemical evaluations and in vivo testing.
What this study cannot tell us
The study primarily focuses on peptide design and in vitro/in vivo models, which may not fully translate to human applications.
Read the original research
Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function.
Proceedings of the National Academy of Sciences of the United States of America, 119(42), e2209044119
Citation
Hawley, Katrina M; Eclov, Rachel J; Schnorenberg, Mathew R; Tian, Yu; Shah, Rhea N; Thomas-Toth, Anika T; Fefferman, Marie; Bird, Gregory H; Walensky, Loren D; Tirrell, Matthew V; LaBelle, James L. (2022). Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function.. Proceedings of the National Academy of Sciences of the United States of America, 119(42), e2209044119. https://doi.org/10.1073/pnas.2209044119